Larubrilstat is a vascular non-inflammatory molecule-1 (VNN1) inhibitor.

Laporolimus is an immunosuppressant.

Kibdelone C is a flavonoid compound found in Kibdelosporangium sp. with anticancer activity, exhibiting GI50 values of less than 1 nM against leukemia cell lines (SR) and renal cancer cell lines (SN12C). Kibdelone C is promising for anticancer research.

KB-208 is a phagocytosis inhibitor that improves immune thrombocytopenia (ITP) in mouse models at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum toxicity biomarkers. KB-208 can be used in immunology research.

Fenoxazoline is a decongestant and a vasoconstrictor.

FA-15 is an phenolic antioxidant. FA-15 has effect on stabilization of reactive fuels.

Ethyl 4-(butylamino)benzoate is an N-alkylated ester derivative of aminobenzoic acid.

DL-Theanine (DL-Glutamic acid γ-ethyl amide) is a natural compound showing tranquilizing effects in the brain.

Cumyl-chsinaca is a synthetic cannabinoid containing indazole-3-carboxamide

BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC50 of 0.1 μM. BPH-742 has antitumor activity.

BPH-628 is an aromatic geranylgeranyl diphosphate synthase (GGPPS) inhibitor, with a pIC50 of 6.1.

BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases.

Amidepin is a new type of antiarrhythmic compound. Amidepin has the activity of regulating cardiac electrical activity. The main regulatory mechanism of amidepin involves ion channel or receptor interaction. Amidepin can be used for the study of arrhythmias.

5,5-Diphenylbarbituric acid is an organic compound belonging to the derivatives of barbituric acid. 5,5-Diphenylbarbituric acid can be used for seizure study.

4F-Docetaxel (4FDT) is a fluorinated docetaxel analog. 4F-Docetaxel has anti-hepatoma activity and can be used for research of hepatocellular carcinoma (HCC).

A potent, selective, orally active orexin-2 receptor (OX2R) antagonist with pKi of 8.0 and 8.1 for human and rat OX2R, respectively.

AM 432 is potent, selective, orally active prostaglandin D2 receptor (DP2/CRTH2) antagonist with binding IC50 of 6 nM for hDP2.AM-432 shows no cross-reactivity against the TP or IP receptors, COX-1 or COX-2 and minimal activity at DP1 receptor. AM432 shows excellent potency in a human whole blood eosinophil shape change assay.AM432 exhibits efficacy in both a murine model of allergic rhinitis and a cigarette smoke induced inflammatory model of COPD.

Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC50 value being 1.8 ±1.5 μM.

A potent and selective inhibitor of sterol O-acyltransferase 2 (SOAT2, ACAT2) with IC50 of 11.8 nM, >6,000-fold selectivity over ACAT1.

A derivative of the antifungal drug itraconazole (ITA) as an inhibitor of MFB cell fate in resident fibroblasts derived from multiple murine and human tissues.

HTS13286 is a selective AQP9 inhibitor with IC50 of 1.5 uM (inhibition of CHO-AQP9 cell water permeability).

2-Amino-2-deoxyglucose hydrochloride is a hexosamine hydrochloride can be used in the synthesis of cyclopropene-modified hexosamine derivative Ac4GlcNCyoc and Ac4GalNCyoc.

PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.

PSMA617-TCMC is a derivative of PSMA-617 with structure modification, in which the caroboxy groups in DOTA ring is replaced by TCMC macrocycle. PSMA-617 is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer,. PSMA-617 originally was developed at the German Cancer Research Center and the Heidelberg University Hospital. ABX held the exclusive license to bring the treatment, which targets prostate-specific membrane antigen (PSMA), through early clinical development.

ICT12035 (AZ2158) is a potent, selective formylpeptide receptor-1 (FPR1) antagonist with IC50 of 30 nM in calcium mobilisation assays (100 nM fMLF).

CW5107 (CW 5107) is a small molecule HSD17B7 inhibitor that enhances oligodendrocyte formation.

Lomeguatrib (PaTrin-2) is a modified guanine base, which can repress the activity of DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (MGMT) with an IC50 value of 6 nM.

Benzocaine hydrochloride is a surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings.

GTP-14564 is a specific kinase inhibitor for ITD-FLT3. GTP-14564 inhibited the growth of interleukin-3-independent Ba/F3 expressing ITD-FLT3 at 1 microM, whereas a 30-fold higher concentration of GTP-14564 was required to inhibit FLT3 ligand-dependent growth of Ba/F3 expressing wild type FLT3 (wt-FLT3).

DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96).